Mechanisms by Which the Type 1 Insulin-like Growth Factor Inhibition Enhances the Effects of Castration on Prostate Cancer Project Leader: Stephen Plymate, M.D. Co-leader: Bruce Montgomery, M.D. The lethal phenotype of prostate cancer is termed androgen-independent (AI), because it develops following castration in the presence of very low levels of
Maximal Targeted Inhibition of Androgen Signaling for Prostate Cancer Therapy Project Leader: Peter Nelson, M.D. Co-leader: Paul Lange, M.D. Clinical and laboratory evidence continues to demonstrate that androgens and the androgen receptor (AR) are the best available targets for treating/preventing both early and advanced prostate cancer. Numerous clinical trials have
Jeremy Jones, Ph.D., Postdoctoral Fellow, University of California, San Francisco
Harris WP, Mostaghel EA, Nelson PS, Montgomery B; Medscape. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009 Feb;6(2):76-85. PubMed PMID: 19198621. Androgen deprivation therapy remains a critical component of treatment for men with advanced prostate cancer, and data support
May 29, 2008: Mark Titus, Ph.D., Assistant Professor, Urologic Oncology, Roswell Park Cancer Institute
